title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Monday,20220418T154044,https://www.benzinga.com/news/22/04/26669813/stocks-that-hit-52-week-lows-on-monday,BPTH,0.005428,Somewhat-Bearish,-0.216618
"Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock  ( NYSE:BMY ) , SenesTech, Inc. - Common Stock  ( NASDAQ:SNES ) ",20231004T160117,https://www.benzinga.com/markets/options/23/10/35092508/stocks-that-hit-52-week-lows-on-wednesday,BPTH,0.012708,Neutral,-0.087032
"Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Aldeyra Therapeutics  ( NASDAQ:ALDX ) , Alignment Healthcare  ( NASDAQ:ALHC ) ",20231016T170953,https://www.benzinga.com/news/23/10/35272489/why-streamline-health-solutions-shares-are-trading-lower-by-over-68-here-are-other-stocks-moving-in,BPTH,0.076236,Neutral,-0.051282
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket,20231016T131535,https://markets.businessinsider.com/news/stocks/why-contrafect-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket-1032708380,BPTH,0.105604,Neutral,-0.050283
"Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Ambrx Biopharma  ( NASDAQ:AMAM ) , Amphenol  ( NYSE:APH ) ",20231016T124712,https://www.benzinga.com/news/23/10/35266067/why-contrafect-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket,BPTH,0.194242,Neutral,-0.067054
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Science Applications Intl  ( NASDAQ:SAIC ) ,20240603T175653,https://www.benzinga.com/news/24/06/39143340/why-science-applications-international-shares-are-trading-lower-by-11-here-are-other-stocks-moving-i,BPTH,0.112182,Neutral,0.060479
Stocks That Hit 52-Week Lows On Friday,20220422T162629,https://www.benzinga.com/markets/options/22/04/26764450/52-weeks-high-and-low-article,BPTH,0.012589,Neutral,0.008217
"Stocks That Hit 52-Week Lows On Tuesday - SoundHound AI  ( NASDAQ:SOUN ) , Sonnet BioTherapeutics  ( NASDAQ:SONN ) ",20221122T154845,https://www.benzinga.com/news/22/11/29825126/stocks-that-hit-52-week-lows-on-tuesday,BPTH,0.028072,Neutral,0.004818
Bio-Path  ( NASDAQ:BPTH )  Receives New Coverage from Analysts at StockNews.com,20230609T055843,https://www.defenseworld.net/2023/06/09/bio-path-nasdaqbpth-receives-new-coverage-from-analysts-at-stocknews-com.html,BPTH,0.930964,Bullish,0.350716
"Earnings Scheduled For March 11, 2022",20220311T090908,https://www.benzinga.com/news/earnings/22/03/26096627/earnings-scheduled-for-march-11-2022,BPTH,0.094912,Neutral,-0.004541
"Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - AgriFORCE Growing Systems  ( NASDAQ:AGRI ) , Apollomics  ( NASDAQ:APLM ) ",20231127T131025,https://www.benzinga.com/news/23/11/35956771/why-up-fintech-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket,BPTH,0.216215,Neutral,-0.008842
"Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Snow Lake Resources  ( NASDAQ:LITM ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20241219T192509,https://www.benzinga.com/24/12/42601428/nasdaq-jumps-100-points-us-initial-jobless-claims-decline,BPTH,0.15347,Somewhat-Bullish,0.271795
"Gold Falls Sharply, Lamb Weston Shares Plunge - Snow Lake Resources  ( NASDAQ:LITM ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20241219T172452,https://www.benzinga.com/24/12/42598636/gold-falls-sharply-lamb-weston-shares-plunge,BPTH,0.154951,Somewhat-Bullish,0.27334
"US Stocks Higher, Micron Reports Downbeat Sales - Aethlon Medical  ( NASDAQ:AEMD ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20241219T153009,https://www.benzinga.com/24/12/42594440/us-stocks-higher-micron-reports-downbeat-sales,BPTH,0.169676,Somewhat-Bullish,0.289139
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity,20241219T120000,https://www.globenewswire.com/news-release/2024/12/19/2999715/0/en/Bio-Path-Holdings-Announces-Preclinical-Testing-of-BP1001-A-as-Potential-Treatment-for-Obesity-in-Type-2-Diabetes-Patients-Enhances-Insulin-Sensitivity.html,BPTH,0.445179,Somewhat-Bullish,0.184941
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients,20241211T120000,https://www.globenewswire.com/news-release/2024/12/11/2995241/0/en/Bio-Path-Holdings-Outlines-Rationale-for-Development-of-BP1001-A-as-Potential-Treatment-for-Obesity-in-Type-2-Diabetes-Patients.html,BPTH,0.250153,Neutral,0.069017
All You Need to Know About Bio-Path  ( BPTH )  Rating Upgrade to Buy,20241120T170010,https://www.zacks.com/stock/news/2372968/all-you-need-to-know-about-bio-path-bpth-rating-upgrade-to-buy,BPTH,0.369685,Bullish,0.374383
"Bio-Path  ( BPTH )  Could Find a Support Soon, Here's Why You Should Buy the Stock Now",20241120T145506,https://www.zacks.com/stock/news/2372806/bio-path-bpth-could-find-a-support-soon-heres-why-you-should-buy-the-stock-now,BPTH,0.421485,Bullish,0.433507
Bio-Path Holdings Reports Third Quarter 2024 Financial Results,20241115T120000,https://www.globenewswire.com/news-release/2024/11/15/2981893/0/en/Bio-Path-Holdings-Reports-Third-Quarter-2024-Financial-Results.html,BPTH,0.333142,Neutral,0.131565
"Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024",20241108T120000,https://www.globenewswire.com/news-release/2024/11/08/2977548/0/en/Bio-Path-Holdings-to-Announce-Third-Quarter-2024-Financial-Results-on-November-15-2024.html,BPTH,0.651499,Neutral,0.116367
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules,20241010T212400,https://www.globenewswire.com/news-release/2024/10/10/2961738/0/en/Bio-Path-Holdings-Announces-Closing-of-4-0-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.291842,Neutral,0.101604
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20241009T000000,https://www.benzinga.com/pressreleases/24/10/g41242061/bio-path-holdings-announces-4-0-million-private-placement-priced-at-the-market-under-nasdaq-rules,BPTH,0.334762,Neutral,0.127085
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules,20241009T000000,https://www.globenewswire.com/news-release/2024/10/09/2960187/0/en/Bio-Path-Holdings-Announces-4-0-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.277658,Neutral,0.114047
"Nasdaq Surges Over 1%; DocuSign Shares Spike Higher - Alternus Clean Energy  ( NASDAQ:ALCE ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20241008T183014,https://www.benzinga.com/markets/equities/24/10/41237197/nasdaq-surges-over-1-docusign-shares-spike-higher,BPTH,0.162255,Neutral,0.149341
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August - Cassava Sciences  ( NASDAQ:SAVA ) ,20241008T161614,https://www.benzinga.com/markets/equities/24/10/41234113/crude-oil-falls-over-4-us-trade-deficit-narrows-in-august,BPTH,0.154951,Neutral,0.145049
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook - PepsiCo  ( NASDAQ:PEP ) ,20241008T135142,https://www.benzinga.com/news/earnings/24/10/41229548/us-stocks-edge-higher-pepsico-cuts-2024-revenue-outlook,BPTH,0.147818,Neutral,0.140996
Why Is Bio-Path Holdings Stock Soaring On Tuesday? - Cassava Sciences  ( NASDAQ:SAVA ) ,20241008T132713,https://www.benzinga.com/general/biotech/24/10/41228945/nano-cap-bio-path-takes-plunge-in-weight-loss-race-initiates-obesity-program-with-drug-candidate-,BPTH,0.555911,Somewhat-Bullish,0.24186
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity,20241008T110000,https://www.globenewswire.com/news-release/2024/10/08/2959544/0/en/Bio-Path-Holdings-Initiates-Development-of-Therapeutic-Program-for-Treatment-of-Obesity.html,BPTH,0.396261,Somewhat-Bullish,0.166971
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference,20240903T110000,https://www.globenewswire.com/news-release/2024/09/03/2939496/0/en/Bio-Path-Holdings-to-Present-at-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html,BPTH,0.434763,Neutral,0.089889
What Happened With Bio-Path Stock Today? - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240821T204950,https://www.benzinga.com/general/biotech/24/08/40495366/what-happened-with-bio-path-stock-today,BPTH,0.790287,Bullish,0.374174
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240821T110000,https://www.benzinga.com/pressreleases/24/08/g40481410/bio-path-holdings-reports-solid-tumor-patient-response-supporting-bp1001-as-compelling-potential-a,BPTH,0.327728,Neutral,0.130221
"Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 - Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20240808T110000,https://www.benzinga.com/pressreleases/24/08/g40247076/bio-path-holdings-to-announce-second-quarter-2024-financial-results-on-august-15-2024,BPTH,0.651499,Neutral,0.109042
Why Bio-Path Stock Is Climbing Today - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240614T130008,https://www.benzinga.com/news/24/06/39331958/why-bio-path-stock-is-climbing-today,BPTH,0.805471,Bullish,0.657267
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240614T110000,https://www.benzinga.com/pressreleases/24/06/g39329287/bio-path-holdings-presents-data-from-ongoing-phase-2-combination-study-of-prexigebersen-for-treatm,BPTH,0.400052,Somewhat-Bullish,0.174541
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress,20240614T110000,https://www.globenewswire.com/news-release/2024/06/14/2898892/0/en/Bio-Path-Holdings-Presents-Data-from-Ongoing-Phase-2-Combination-Study-of-Prexigebersen-for-Treatment-of-Acute-Myeloid-Leukemia-at-European-Hematology-Association-Congress.html,BPTH,0.344473,Somewhat-Bullish,0.16418
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules,20240605T214600,https://www.globenewswire.com/news-release/2024/06/05/2894340/0/en/Bio-Path-Holdings-Announces-Closing-of-4-0-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.310283,Neutral,0.052288
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules,20240604T120000,https://www.globenewswire.com/news-release/2024/06/04/2892970/0/en/Bio-Path-Holdings-Announces-4-0-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.29792,Neutral,0.074697
Dow Dips Over 300 Points; GameStop Shares Spike Higher - Science Applications Intl  ( NASDAQ:SAIC ) ,20240603T183514,https://www.benzinga.com/news/earnings/24/06/39144239/dow-dips-over-300-points-gamestop-shares-spike-higher,BPTH,0.13347,Neutral,0.068812
Crude Oil Down Over 3%; US Construction Spending Falls In May - Lattice Semiconductor  ( NASDAQ:LSCC ) ,20240603T160007,https://www.benzinga.com/news/earnings/24/06/39141026/crude-oil-down-over-3-us-construction-spending-falls-in-may,BPTH,0.144708,Neutral,0.071885
What's Going On With Bio-Path Stock? - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240603T140804,https://www.benzinga.com/news/24/06/39138161/whats-going-on-with-bio-path-stock,BPTH,0.595343,Bullish,0.372254
Nasdaq Surges 150 Points; US Manufacturing PMI Rises In May - CalAmp  ( NASDAQ:CAMP ) ,20240603T135410,https://www.benzinga.com/news/earnings/24/06/39137733/nasdaq-surges-150-points-us-manufacturing-pmi-rises-in-may,BPTH,0.246167,Neutral,0.096516
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20240603T110000,https://www.globenewswire.com/news-release/2024/06/03/2892094/0/en/Bio-Path-Holdings-Presents-Data-from-Ongoing-Phase-2-Combination-Study-of-Prexigebersen-for-Treatment-of-Acute-Myeloid-Leukemia-at-American-Society-of-Clinical-Oncology-ASCO-Annual.html,BPTH,0.349329,Neutral,0.067666
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240524T110000,https://www.benzinga.com/pressreleases/24/05/g39004731/bio-path-holdings-to-present-data-at-2024-european-hematology-association-congress,BPTH,0.458708,Somewhat-Bullish,0.1933
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress,20240524T110000,https://www.globenewswire.com/news-release/2024/05/24/2887897/0/en/Bio-Path-Holdings-to-Present-Data-at-2024-European-Hematology-Association-Congress.html,BPTH,0.395903,Somewhat-Bullish,0.180587
Bio-Path Holdings Reports First Quarter 2024 Financial Results,20240515T110000,https://www.globenewswire.com/news-release/2024/05/15/2882254/0/en/Bio-Path-Holdings-Reports-First-Quarter-2024-Financial-Results.html,BPTH,0.470555,Somewhat-Bullish,0.236496
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20240506T090900,https://www.defenseworld.net/2024/05/06/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.861522,Bullish,0.524909
Looking Into Bio-Path Hldgs's Recent Short Interest - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240501T180029,https://www.benzinga.com/insights/short-sellers/24/05/38561107/looking-into-bio-path-hldgss-recent-short-interest,BPTH,0.404563,Somewhat-Bullish,0.243674
"Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20240419T161404,https://www.benzinga.com/pressreleases/24/04/g38338145/bio-path-holdings-inc-announces-closing-of-1-2-million-registered-direct-offering-priced-at-the-ma,BPTH,0.472672,Neutral,0.145676
"Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules",20240419T161400,https://www.globenewswire.com/news-release/2024/04/19/2866293/0/en/Bio-Path-Holdings-Inc-Announces-Closing-of-1-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.461006,Neutral,0.149334
Bio-Path  ( BPTH )  Rises on Upbeat Updates From Blood Cancer Study,20240419T141400,https://www.zacks.com/stock/news/2258537/bio-path-bpth-rises-on-upbeat-updates-from-blood-cancer-study,BPTH,0.482406,Bullish,0.356503
"Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Adaptive Biotechnologies  ( NASDAQ:ADPT ) , AGBA Group Holding  ( NASDAQ:AGBA ) ",20240419T094548,https://www.benzinga.com/news/24/04/38330517/why-wang-lee-group-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket,BPTH,0.185781,Neutral,0.0
"Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules",20240418T175700,https://www.globenewswire.com/news-release/2024/04/18/2865747/0/en/Bio-Path-Holdings-Inc-Announces-1-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,BPTH,0.449045,Somewhat-Bullish,0.172771
"Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher - AGBA Group Holding  ( NASDAQ:AGBA ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20240418T160824,https://www.benzinga.com/news/earnings/24/04/38319117/crude-oil-edges-lower-bio-path-holdings-shares-spike-higher,BPTH,0.139669,Somewhat-Bullish,0.265218
"Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings - AGBA Group Holding  ( NASDAQ:AGBA ) , iLearningEngines  ( NASDAQ:AILE ) ",20240418T140448,https://www.benzinga.com/news/earnings/24/04/38315588/dow-surges-over-100-points-d-r-horton-posts-upbeat-earnings,BPTH,0.148731,Somewhat-Bullish,0.274467
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated by Analysts at StockNews.com,20240416T062842,https://www.defenseworld.net/2024/04/16/bio-path-nasdaqbpth-coverage-initiated-by-analysts-at-stocknews-com.html,BPTH,0.869371,Bullish,0.489546
Bio-Path Holdings Expands Global Patent Portfolio - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240415T110000,https://www.benzinga.com/pressreleases/24/04/g38244784/bio-path-holdings-expands-global-patent-portfolio,BPTH,0.498188,Neutral,0.144912
Bio-Path Holdings Expands Global Patent Portfolio,20240415T110000,https://www.globenewswire.com/news-release/2024/04/15/2862615/0/en/Bio-Path-Holdings-Expands-Global-Patent-Portfolio.html,BPTH,0.4499,Neutral,0.138868
Bio-Path Holdings Provides 2024 Clinical and Operational Update - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240402T110000,https://www.benzinga.com/pressreleases/24/04/g38041424/bio-path-holdings-provides-2024-clinical-and-operational-update,BPTH,0.342685,Neutral,0.066235
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20240331T071242,https://www.defenseworld.net/2024/03/31/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.891493,Bullish,0.594877
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20240315T070843,https://www.defenseworld.net/2024/03/15/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.900454,Bullish,0.535205
Why Bio-Path Holdings Shares Are Falling Today - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240308T171719,https://www.benzinga.com/news/earnings/24/03/37564342/why-bio-path-holdings-shares-are-falling-today,BPTH,0.729067,Neutral,0.085705
Bio-Path Holdings Reports Full Year 2023 Financial Results,20240308T120000,https://www.globenewswire.com/news-release/2024/03/08/2843016/0/en/Bio-Path-Holdings-Reports-Full-Year-2023-Financial-Results.html,BPTH,0.35106,Neutral,0.136584
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20240307T075841,https://www.defenseworld.net/2024/03/07/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.937963,Bullish,0.516093
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20240301T092442,https://www.defenseworld.net/2024/03/01/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth-2.html,BPTH,0.857533,Bullish,0.539504
Bio-Path  ( NASDAQ:BPTH )  Receives New Coverage from Analysts at StockNews.com,20240228T072128,https://www.americanbankingnews.com/2024/02/28/bio-path-nasdaqbpth-receives-new-coverage-from-analysts-at-stocknews-com.html,BPTH,0.922387,Bullish,0.458187
Bio-Path  ( NASDAQ:BPTH )  Receives New Coverage from Analysts at StockNews.com,20240228T072045,https://www.defenseworld.net/2024/02/28/bio-path-nasdaqbpth-receives-new-coverage-from-analysts-at-stocknews-com.html,BPTH,0.907478,Bullish,0.47003
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240221T120000,https://www.benzinga.com/pressreleases/24/02/g37232519/bio-path-holdings-announces-1-for-20-reverse-stock-split,BPTH,0.411176,Neutral,0.134025
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split,20240221T120000,https://www.globenewswire.com/news-release/2024/02/21/2832603/0/en/Bio-Path-Holdings-Announces-1-for-20-Reverse-Stock-Split.html,BPTH,0.348103,Neutral,0.121472
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20240220T073641,https://www.defenseworld.net/2024/02/20/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.929012,Bullish,0.60774
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20240110T120000,https://www.benzinga.com/pressreleases/24/01/g36573014/bio-path-holdings-announces-completion-of-first-dose-cohort-in-phase-1-clinical-trial-evaluating-b,BPTH,0.474688,Neutral,0.108075
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20240103T063446,https://www.defenseworld.net/2024/01/03/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.887767,Bullish,0.497965
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20231226T062646,https://www.defenseworld.net/2023/12/26/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.877135,Bullish,0.461025
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20231218T063244,https://www.defenseworld.net/2023/12/18/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.859085,Bullish,0.415652
Texas Biotech Advances Lead Candidate in Resistant AML,20231215T164742,https://www.investorideas.com/news/2023/biotech/12151Texas-Biotech.asp,BPTH,0.497391,Somewhat-Bullish,0.341557
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia,20231214T120000,https://www.globenewswire.com/news-release/2023/12/14/2796128/0/en/Bio-Path-Holdings-Successfully-Completes-First-Dose-Cohort-of-Phase-1-1b-Clinical-Trial-of-BP1002-in-Refractory-Relapsed-Acute-Myeloid-Leukemia.html,BPTH,0.319414,Neutral,0.136644
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20231202T062241,https://www.defenseworld.net/2023/12/02/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.900307,Bullish,0.498238
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated by Analysts at StockNews.com,20231124T081442,https://www.defenseworld.net/2023/11/24/bio-path-nasdaqbpth-coverage-initiated-by-analysts-at-stocknews-com-2.html,BPTH,0.85773,Bullish,0.474984
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated by Analysts at StockNews.com,20231116T090050,https://www.defenseworld.net/2023/11/16/bio-path-nasdaqbpth-coverage-initiated-by-analysts-at-stocknews-com.html,BPTH,0.854205,Bullish,0.442106
"Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023 - Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20231108T120000,https://www.benzinga.com/pressreleases/23/11/g35669300/bio-path-holdings-to-announce-third-quarter-2023-financial-results-on-november-15-2023,BPTH,0.696319,Neutral,0.112502
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20231108T081843,https://www.defenseworld.net/2023/11/08/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth-2.html,BPTH,0.866386,Somewhat-Bullish,0.303597
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20231031T072647,https://www.defenseworld.net/2023/10/31/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com-2.html,BPTH,0.894071,Bullish,0.480994
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20231024T110000,https://www.benzinga.com/pressreleases/23/10/g35389753/bio-path-holdings-to-host-virtual-key-opinion-leader-event-to-discuss-prexigebersen-and-advances-i,BPTH,0.678102,Somewhat-Bullish,0.18755
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20231023T072447,https://www.defenseworld.net/2023/10/23/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.846873,Bullish,0.38999
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20231023T072446,https://www.defenseworld.net/2023/10/23/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.894071,Bullish,0.464651
"Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Biocept  ( NASDAQ:BIOC ) , Advent Technologies Hldgs  ( NASDAQ:ADN ) ",20231018T121855,https://www.benzinga.com/news/23/10/35305719/why-talaris-therapeutics-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket,BPTH,0.142989,Bearish,-0.389355
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20231015T070643,https://www.defenseworld.net/2023/10/15/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.902368,Bullish,0.42297
What's Going On With Bio-Path Holdings Stock? - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20231013T143210,https://www.benzinga.com/news/23/10/35241983/whats-going-on-with-bio-path-holdings-stock,BPTH,0.88837,Somewhat-Bullish,0.23323
"Dow Jumps Over 200 Points; JPMorgan Earnings Top Estimates - Bellerophon Therapeutics  ( NASDAQ:BLPH ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20231013T134849,https://www.benzinga.com/news/earnings/23/10/35241137/dow-jumps-over-200-points-jpmorgan-earnings-top-estimates,BPTH,0.173333,Bullish,0.462523
"Why Comtech Telecommunications Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Blue Star Foods  ( NASDAQ:BSFC ) , Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20231013T113538,https://www.benzinga.com/news/23/10/35238161/why-comtech-telecommunications-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-prem,BPTH,0.162802,Bullish,0.462461
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20231007T073245,https://www.defenseworld.net/2023/10/07/bio-path-nasdaqbpth-now-covered-by-stocknews-com-2.html,BPTH,0.85773,Bullish,0.456528
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230929T072442,https://www.defenseworld.net/2023/09/29/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.872847,Bullish,0.400637
Bio-Path  ( NASDAQ:BPTH )  Receives New Coverage from Analysts at StockNews.com,20230921T073445,https://www.defenseworld.net/2023/09/21/bio-path-nasdaqbpth-receives-new-coverage-from-analysts-at-stocknews-com.html,BPTH,0.832201,Somewhat-Bullish,0.311926
Bio-Path Receives Sell Rating from StockNews.com,20230917T064921,https://www.claytoncountyregister.com/news2/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com/431361/,BPTH,0.759278,Somewhat-Bullish,0.172444
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20230914T084250,https://www.defenseworld.net/2023/09/14/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.906461,Bullish,0.410508
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference,20230908T200100,https://www.globenewswire.com/news-release/2023/09/08/2740314/0/en/Bio-Path-Holdings-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,BPTH,0.433523,Neutral,0.089706
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230905T072445,https://www.defenseworld.net/2023/09/05/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com-2.html,BPTH,0.883531,Bullish,0.426277
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230828T064244,https://www.defenseworld.net/2023/08/28/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.868543,Bullish,0.511394
Bio-Path  ( NASDAQ:BPTH )  Receives New Coverage from Analysts at StockNews.com,20230820T055243,https://www.defenseworld.net/2023/08/20/bio-path-nasdaqbpth-receives-new-coverage-from-analysts-at-stocknews-com.html,BPTH,0.874993,Bullish,0.409103
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated by Analysts at StockNews.com,20230812T052247,https://www.defenseworld.net/2023/08/12/bio-path-nasdaqbpth-coverage-initiated-by-analysts-at-stocknews-com.html,BPTH,0.870696,Bullish,0.472445
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230804T073844,https://www.defenseworld.net/2023/08/04/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.868543,Bullish,0.444156
Why Bio-Path Holdings  ( BPTH )  Stock Is Down 45% - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20230803T173800,https://www.benzinga.com/news/23/08/33554961/why-bio-path-holdings-bpth-stock-is-down-45,BPTH,0.83383,Neutral,-0.008275
"Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering - Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20230803T122237,https://www.benzinga.com/pressreleases/23/08/g33547210/bio-path-holdings-inc-announces-pricing-of-2-1-million-public-offering,BPTH,0.386875,Neutral,0.101269
"Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering",20230803T122200,https://www.globenewswire.com/news-release/2023/08/03/2718012/0/en/Bio-Path-Holdings-Inc-Announces-Pricing-of-2-1-Million-Public-Offering.html,BPTH,0.352432,Neutral,0.097063
Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia - Bio-Path Hldgs  ( NASDAQ:BPTH ) ,20230801T195426,https://www.benzinga.com/general/biotech/23/08/33495093/bio-path-releases-early-cut-data-from-mid-stage-prexigebersen-trial-in-acute-myeloid-leukemia,BPTH,0.392948,Bullish,0.385146
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20230727T075244,https://www.defenseworld.net/2023/07/27/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.879272,Bullish,0.352588
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230719T053642,https://www.defenseworld.net/2023/07/19/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com-2.html,BPTH,0.861522,Bullish,0.409553
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors,20230717T110000,https://www.globenewswire.com/news-release/2023/07/17/2705155/0/en/Bio-Path-Holdings-Announces-Successful-Completion-of-First-Dose-Cohort-in-Phase-1-1b-Clinical-Trial-of-BP1001-A-in-Solid-Tumors.html,BPTH,0.29485,Neutral,0.070346
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20230711T053850,https://www.defenseworld.net/2023/07/11/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.917585,Bullish,0.451883
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230703T052246,https://www.defenseworld.net/2023/07/03/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.962559,Bullish,0.470388
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20230625T051847,https://www.defenseworld.net/2023/06/25/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.949596,Bullish,0.407514
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230617T052243,https://www.defenseworld.net/2023/06/17/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.945787,Bullish,0.478074
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20230524T053455,https://www.defenseworld.net/2023/05/24/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.948824,Bullish,0.414244
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20230516T054845,https://www.defenseworld.net/2023/05/16/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.925058,Bullish,0.368901
Bio-Path Holdings Reports First Quarter 2023 Financial Results,20230512T110000,https://www.globenewswire.com/news-release/2023/05/12/2667656/0/en/Bio-Path-Holdings-Reports-First-Quarter-2023-Financial-Results.html,BPTH,0.346278,Somewhat-Bullish,0.151797
"Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023 - Bio-Path Hldgs  ( NASDAQ:BPTH ) ",20230505T110000,https://www.benzinga.com/pressreleases/23/05/g32235036/bio-path-holdings-to-announce-first-quarter-2023-financial-results-on-may-12-2023,BPTH,0.696319,Neutral,0.112499
"Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023",20230505T110000,https://www.globenewswire.com/news-release/2023/05/05/2662411/0/en/Bio-Path-Holdings-to-Announce-First-Quarter-2023-Financial-Results-on-May-12-2023.html,BPTH,0.651499,Neutral,0.116352
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230430T051244,https://www.defenseworld.net/2023/04/30/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.956537,Bullish,0.47074
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230422T053642,https://www.defenseworld.net/2023/04/22/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.941669,Bullish,0.420374
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20230414T054044,https://www.defenseworld.net/2023/04/14/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.9545,Somewhat-Bullish,0.257517
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230406T053447,https://www.defenseworld.net/2023/04/06/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.91848,Bullish,0.356447
Bio-Path Holdings Reports Full Year 2022 Financial Results,20230331T110000,https://www.globenewswire.com/news-release/2023/03/31/2638506/0/en/Bio-Path-Holdings-Reports-Full-Year-2022-Financial-Results.html,BPTH,0.351115,Somewhat-Bullish,0.157781
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20230329T052642,https://www.defenseworld.net/2023/03/29/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.890401,Somewhat-Bullish,0.320659
"Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 - Bio-Path Holdings  ( NASDAQ:BPTH ) ",20230324T200100,https://www.benzinga.com/pressreleases/23/03/g31497654/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-march-31-2023,BPTH,0.677342,Neutral,0.118373
"Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023",20230324T200100,https://www.globenewswire.com/news-release/2023/03/24/2634308/0/en/Bio-Path-Holdings-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-31-2023.html,BPTH,0.630923,Neutral,0.125099
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20230321T052649,https://www.defenseworld.net/2023/03/21/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.939207,Somewhat-Bullish,0.240262
Bio-Path Holdings Provides Clinical and Operational Update,20230316T110000,https://www.globenewswire.com/news-release/2023/03/16/2628469/0/en/Bio-Path-Holdings-Provides-Clinical-and-Operational-Update.html,BPTH,0.278697,Somewhat-Bullish,0.150848
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20230305T082443,https://www.defenseworld.net/2023/03/05/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.955602,Bullish,0.450609
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230217T082245,https://www.defenseworld.net/2023/02/17/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.943973,Somewhat-Bullish,0.292579
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230209T084243,https://www.etfdailynews.com/2023/02/09/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com/,BPTH,0.89699,Somewhat-Bullish,0.257118
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230209T084241,https://www.defenseworld.net/2023/02/09/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.89699,Somewhat-Bullish,0.257118
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230201T082845,https://www.defenseworld.net/2023/02/01/bio-path-nasdaqbpth-now-covered-by-stocknews-com-2.html,BPTH,0.904419,Bullish,0.395015
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230201T082843,https://www.etfdailynews.com/2023/02/01/bio-path-nasdaqbpth-now-covered-by-stocknews-com-2/,BPTH,0.904419,Bullish,0.395015
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20230124T082846,https://reporter.am/2023/01/24/bio-path-nasdaqbpth-now-covered-by-stocknews-com.html,BPTH,0.902573,Somewhat-Bullish,0.281764
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230116T090642,https://reporter.am/2023/01/16/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com-2.html,BPTH,0.92757,Somewhat-Bullish,0.331395
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20230108T082244,https://www.etfdailynews.com/2023/01/08/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com/,BPTH,0.920636,Somewhat-Bullish,0.238509
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221231T082246,https://www.etfdailynews.com/2022/12/31/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth-2/,BPTH,0.948591,Somewhat-Bullish,0.341092
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221231T082244,https://reporter.am/2022/12/31/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.935953,Bullish,0.354658
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221223T082446,https://www.etfdailynews.com/2022/12/23/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth/,BPTH,0.908087,Somewhat-Bullish,0.326046
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221223T082444,https://reporter.am/2022/12/23/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth-2.html,BPTH,0.908087,Somewhat-Bullish,0.326046
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20221215T084845,https://www.etfdailynews.com/2022/12/15/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com-2/,BPTH,0.971549,Somewhat-Bullish,0.324799
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors,20221207T120000,https://www.globenewswire.com/news-release/2022/12/07/2569142/0/en/Bio-Path-Holdings-Announces-First-Patient-Dosed-in-Phase-1-1b-Clinical-Trial-of-BP1001-A-in-Solid-Tumors.html,BPTH,0.343619,Neutral,0.121129
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20221207T084244,https://reporter.am/2022/12/07/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.967875,Bullish,0.409582
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221129T082451,https://www.etfdailynews.com/2022/11/29/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth/,BPTH,0.940545,Bullish,0.403117
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221129T082448,https://reporter.am/2022/11/29/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth.html,BPTH,0.93513,Bullish,0.40662
Analyzing Bio-Path Holdings's Short Interest - Bio-Path Holdings  ( NASDAQ:BPTH ) ,20221128T163720,https://www.benzinga.com/short-sellers/22/11/29872564/analyzing-bio-path-holdingss-short-interest,BPTH,0.426824,Somewhat-Bullish,0.247129
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20221121T083043,https://www.etfdailynews.com/2022/11/21/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com/,BPTH,0.962982,Somewhat-Bullish,0.335331
Bio-Path Holdings Reports Third Quarter 2022 Financial Results,20221115T120000,https://www.globenewswire.com/news-release/2022/11/15/2555958/0/en/Bio-Path-Holdings-Reports-Third-Quarter-2022-Financial-Results.html,BPTH,0.435328,Somewhat-Bullish,0.180663
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20221113T081048,https://www.etfdailynews.com/2022/11/13/bio-path-nasdaqbpth-now-covered-by-stocknews-com/,BPTH,0.913524,Somewhat-Bullish,0.239272
"Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022 - Bio-Path Holdings  ( NASDAQ:BPTH ) ",20221108T120000,https://www.benzinga.com/pressreleases/22/11/g29610530/bio-path-holdings-to-announce-third-quarter-2022-financial-results-on-november-15-2022,BPTH,0.682689,Neutral,0.122499
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221028T062645,https://www.etfdailynews.com/2022/10/28/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth/,BPTH,0.929273,Bullish,0.428981
StockNews.com Initiates Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20221028T062640,https://reporter.am/2022/10/28/stocknews-com-initiates-coverage-on-bio-path-nasdaqbpth-2.html,BPTH,0.922387,Bullish,0.408376
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients,20221024T110000,https://www.globenewswire.com/news-release/2022/10/24/2539808/0/en/Bio-Path-Holdings-Announces-First-Patient-Dosed-in-Phase-1-1b-Study-of-BP1002-in-Refractory-Relapsed-Acute-Myeloid-Leukemia-Patients.html,BPTH,0.328455,Somewhat-Bullish,0.179202
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220926T062841,https://reporter.am/2022/09/26/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com-2.html,BPTH,0.929273,Somewhat-Bullish,0.337403
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220911T083441,https://reporter.am/2022/09/11/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.939207,Bullish,0.410382
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220910T061245,https://www.etfdailynews.com/2022/09/10/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com/,BPTH,0.956692,Bullish,0.415995
Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference,20220906T110000,https://www.globenewswire.com/news-release/2022/09/06/2510176/0/en/Bio-Path-Holdings-to-Present-at-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html,BPTH,0.592095,Neutral,0.090442
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20220827T072642,https://reporter.am/2022/08/27/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.965957,Bullish,0.423827
Bio-Path  ( NASDAQ:BPTH )  Now Covered by StockNews.com,20220819T081642,https://reporter.am/2022/08/19/bio-path-nasdaqbpth-now-covered-by-stocknews-com-2.html,BPTH,0.933751,Bullish,0.398931
StockNews.com Begins Coverage on Bio-Path  ( NASDAQ:BPTH ) ,20220817T062845,https://www.etfdailynews.com/2022/08/17/stocknews-com-begins-coverage-on-bio-path-nasdaqbpth/,BPTH,0.948339,Somewhat-Bullish,0.34622
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220817T062842,https://www.defenseworld.net/2022/08/17/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com-2.html,BPTH,0.961964,Bullish,0.387857
"Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022",20220809T110000,https://www.globenewswire.com/news-release/2022/08/09/2494661/0/en/Bio-Path-Holdings-to-Announce-Second-Quarter-2022-Financial-Results-on-August-16-2022.html,BPTH,0.636698,Neutral,0.125688
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220809T063249,https://www.etfdailynews.com/2022/08/09/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com/,BPTH,0.929556,Bullish,0.358281
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220809T063242,https://www.defenseworld.net/2022/08/09/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.92528,Bullish,0.43572
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220802T092242,https://reporter.am/2022/08/02/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.937859,Bullish,0.410282
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220801T062841,https://www.etfdailynews.com/2022/08/01/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com/,BPTH,0.916507,Somewhat-Bullish,0.203018
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20220726T064642,https://reporter.am/2022/07/26/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.916507,Bullish,0.352544
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220712T065844,https://reporter.am/2022/07/12/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.932362,Somewhat-Bullish,0.288094
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated by Analysts at StockNews.com,20220708T052449,https://www.etfdailynews.com/2022/07/08/bio-path-nasdaqbpth-coverage-initiated-by-analysts-at-stocknews-com/,BPTH,0.895798,Neutral,0.001358
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220622T052041,https://www.defenseworld.net/2022/06/22/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com-5.html,BPTH,0.866386,Neutral,0.011707
Bio-Path  ( NASDAQ:BPTH )  Coverage Initiated at StockNews.com,20220606T051841,https://www.defenseworld.net/2022/06/06/bio-path-nasdaqbpth-coverage-initiated-at-stocknews-com.html,BPTH,0.913524,Neutral,0.005307
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20220529T050849,https://www.etfdailynews.com/2022/05/29/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com/,BPTH,0.907304,Neutral,0.003259
"The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation",20220517T130455,https://www.benzinga.com/general/biotech/22/05/27249090/the-daily-biotech-pulse-pfizer-biontechs-covid-19-booster-for-5-11-year-kids-soon-ultragenyx-in-l,BPTH,0.08978,Neutral,0.001205
Bio-Path Holdings: Q1 Earnings Insights,20220517T114658,https://www.benzinga.com/news/earnings/22/05/27245924/bio-path-holdings-q1-earnings-insights,BPTH,0.908999,Neutral,-0.013119
"Earnings Scheduled For May 17, 2022",20220517T084725,https://www.benzinga.com/news/earnings/22/05/27243756/earnings-scheduled-for-may-17-2022,BPTH,0.121435,Neutral,-0.023857
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220505T053041,https://www.defenseworld.net/2022/05/05/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.886691,Neutral,0.011032
Bio-Path  ( NASDAQ:BPTH )  Now Covered by Analysts at StockNews.com,20220427T052241,https://www.defenseworld.net/2022/04/27/bio-path-nasdaqbpth-now-covered-by-analysts-at-stocknews-com.html,BPTH,0.868503,Neutral,0.015738
Bio-Path  ( NASDAQ:BPTH )  Research Coverage Started at StockNews.com,20220420T073041,https://decaymag.com/2022/04/20/bio-path-nasdaqbpth-research-coverage-started-at-stocknews-com.html,BPTH,0.883396,Neutral,0.001773
Bio-Path  ( NASDAQ:BPTH )  Earns Sell Rating from Analysts at StockNews.com,20220414T061041,https://www.defenseworld.net/2022/04/14/bio-path-nasdaqbpth-earns-sell-rating-from-analysts-at-stocknews-com.html,BPTH,0.9205,Neutral,0.003557
Why Bio-Path Holdings Shares Are Rising After Hours,20220412T205527,https://www.benzinga.com/general/biotech/22/04/26604438/why-bio-path-holdings-shares-are-rising-after-hours,BPTH,0.742397,Neutral,0.022265
"The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China",20220311T125204,https://www.benzinga.com/general/biotech/22/03/26098907/the-daily-biotech-pulse-valneva-gains-on-covid-shot-regulatory-update-lucira-health-and-clearside,BPTH,0.146425,Neutral,0.000279
Bio-Path Holdings: Q4 Earnings Insights,20220311T124939,https://www.benzinga.com/news/earnings/22/03/26099218/bio-path-holdings-q4-earnings-insights,BPTH,0.65833,Neutral,-0.016795
Bio-Path Holdings Reports Full Year 2021 Financial Results,20220311T120000,https://www.globenewswire.com/news-release/2022/03/11/2401728/0/en/Bio-Path-Holdings-Reports-Full-Year-2021-Financial-Results.html,BPTH,0.359512,Bullish,0.368746
